ClinicalTrials.gg
Active, not recruitingNCT04245514Updated Oct 23, 2026

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Durvalumab and Radiotherapy in Non-small Cell Lung Cancer and NSCLC, sponsored by Swiss Cancer Institute. Active, not recruiting at 13 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Swiss Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 23, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
39th of 94
90 · median 74
Started
2020
with 13 others
Phase 2
58 of 94
11 open now
Primary completion
2026-12
later than 21 of 36 live
Registered
54th of 94
by date
Lead sponsor
3 of 94
Swiss Cancer Institute

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by planned enrollment, is one of 14 that started in 2020, is one of 58 in phase 2, reaches primary completion later than 21 of the 36 other live ones, and was the 54th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy. Neo-adjuvant immunotherapy is a promising additional treatment modality aiming at increasing local control and better tackling micrometastases at the time of radical local treatment. Radiotherapy is thought to act synergistically with immunotherapy through release of tumor antigens and modulation of the local immune microenvironment in favor of a better antigen-presentation and (systemic) anti-tumor immune response (abscopal effect).

The aim of the proposed SAKK 16/18 trial is to evaluate the efficacy and safety of adding immune-modulatory radiotherapy to the SAKK 16/14 treatment regimen by combining neo-adjuvant radio-immunotherapy. Due to the lack of evidence for an optimal radiotherapy regimen for an "in-situ vaccination" effect three different radiotherapy regimens will be tested.

Read the detailed description

In resectable locally advanced lung cancer there is an urgent need for more efficacious therapy, since most of the patients will eventually have a relapse and will die of the disease. Distant metastases are the main site of recurrence. Therefore, the most promising treatment strategy is to better eliminate micrometastases present at the time of diagnosis through improved systemic treatment. In this regard, the SAKK 16/14 trial is investigating the efficacy of the anti-PD-L1 inhibitor durvalumab before and after surgery added to standard neoadjuvant chemotherapy with cisplatin/docetaxel. It has just completed accrual as of Q1 2019.

The primary aim of the SAKK 16/18 trial is to evaluate the efficacy and safety of adding immune-modulatory radiotherapy to the SAKK 16/14 treatment regimen by combining it with neoadjuvant immunotherapy. Due to the lack of evidence for an optimal immune-modulatory radiotherapy regimen we test 3 different radiotherapy regimens to investigate differences in efficacy and tolerability as key exploratory endpoint.

Neoadjuvant therapy is the optimal setting to test the combination of immune-modulatory radiotherapy and immune checkpoint inhibitor therapy. Resection of the primary tumor and mediastinal lymph nodes will allow to investigate pathological responses and nodal downstaging at an early time point. Furthermore, this setting allows for extensive translational research evaluating cellular and molecular mechanisms of anti-tumor immune response.

SAKK 16/18 is a prospective, multicenter, phase II trial with 3 radiotherapy cohorts.

The treatment consists of

  • Neoadjuvant chemotherapy with cisplatin and docetaxel: 3 cycles of 21 days
  • Neoadjuvant immunotherapy with durvalumab: 1 cycle
  • Neoadjuvant immune-modulatory radiotherapy

    • Concurrent with neoadjuvant immunotherapy
    • Random assignment to one of the following fractionation regimens:

      • 20x2 Gy (weekdaily, 4 weeks)
      • 5x5 Gy (weekdaily, 1 week)
      • 3x8 Gy (on alternate days, 1 week)
  • Surgery

    o Between 4 and 6 weeks after the application of durvalumab (independent of the radiotherapy regimen)

  • If indicated: Postoperative radiotherapy (should start between 3 to 6 weeks after surgery)
  • Adjuvant immunotherapy with durvalumab: 13 cycles of 28 days
03

Conditions studied

  • Non-small Cell Lung Cancer
  • NSCLC

Keywords

  • Immune-modulatory radiotherapy
  • neoadjuvant PD-L1 blockade
  • neoadjuvant chemotherapy
  • non-small cell lung cancer (NSCLC)
  • NSCLC
  • Surgery
  • abscopal effect
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written according to ICH-GCP regulations before registration and prior to any trial specific procedures.
  • Histologically (cytology is accepted if histology is not possible) confirmed NSCLC (adeno-, squamous-, large cell carcinoma, or NSCLC not otherwise specified (NOS)) irrespective of genomic aberrations or expression status.
  • Tumor stage T1-4>7 N2 M0 (i.e. T1-3 N2 or T4 N2 but T4 only allowed if due to size > 7cm, not allowed if due to invasion or nodule in different ipsilateral lobe), according to the TNM classification, 8th edition, December 2016 (see Appendix 2). Mediastinal lymph node staging has to follow the process chart.
  • Tumor is considered resectable based on a multidisciplinary tumor board decision made before treatment. Resectable is when a complete resection can be achieved according to Rami-Porta
  • Patients with a prior (except NSCLC) and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence, after consultation with CI.
  • per v1.1 criteria by PET/CT with contrast enhanced CT-scan.
  • Tumor tissue is available for the mandatory translational research (formalin-fixed; preferably histology, cytology allowed if histology is not possible)
  • Age 18-75 years at time of registration
  • 0-1
  • Adequate bone marrow function: ≥ 1.5 x 109/L, count ≥ 100 x 109/L, ≥ 90 g/L (transfusion allowed)
  • Adequate hepatic function: total ≤ 1.5 x (except for patients with Gilbert's disease ≤ 3.0 x ULN), and ALT ≤ 1.5 x ULN, AP ≤ 2.5 x ULN.
  • Adequate renal function: calculated ≥ 60 mL/min, according to the formula of Cockcroft-Gault
  • Appropriate lung function based on the ESTS guidelines:

    • For pneumonectomy: and DLCO ≥80%. If one of both \<80%, an exercise test peak VO2 >75% or 20ml/kg/min is needed
    • For resection less than pneumonectomy (resection up to the calculated extent): exercise test peak VO2 ≥35% or ≥10ml/kg/min, with predicted postoperative FEV1 and DLCO ≥ 30%.
    • NB: if Spiroergometry would be needed according to ESTS guidelines but is not possible in due time due to patient factors or the center's resources alternative assessment methods of fitness for resection can be used (e.g. Stair climbing test, V/P scan)
  • Adequate cardiac function according to investigator's decision based on evaluation of risk according to classification
  • Women of must use highly effective , are not pregnant or lactating and agree not to become pregnant during trial treatment and until 90 days after the last dose of drug. A negative pregnancy test performed within 7 days before registration is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 90 days after the last dose of investigational drug.

Exclusion criteria

Exclusion criteria:

  • Presence of any distant or N3 disease. have to be excluded by CT or MRI.
  • Sulcus superior tumors (Pancoast tumors) or T4 for any other reason than size >7cm.
  • Any previous treatment for NSCLC
  • Any previous treatment with , including durvalumab
  • Previous radiotherapy to the chest (with the exception of tangential breast irradiation with minimal dose to lung and mediastinum, and superficial orthovoltage or electron irradiation of localized skin lesions)
  • Concomitant or recent (within 30 days of registration) treatment with any other experimental drug and/or enrollment in another clinical trial.
  • Concomitant use of other anti-cancer drugs or radiotherapy.
  • Severe or uncontrolled cardiovascular disease (congestive heart failure III or IV) unstable angina pectoris, history of myocardial infarction within the last three months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia), uncontrolled hypertension.
  • Preexisting peripheral neuropathy (> Grade 1)
  • Body weight less than 30 kg
  • Known history of (HIV) or active chronic or virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.
  • Known history of allogeneic organ transplant
  • Active disease or a syndrome requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease. Exceptions: vitiligo, resolved childhood asthma/atopy, hypothyroidism stable on hormone replacement, Sjögren's syndrome
  • Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
  • Concomitant or prior use of medication within 28 days before registration, with the exceptions of intranasal and inhaled , or systemic corticosteroids which must not exceed 10 mg/day of prednisone or a dose equivalent corticosteroid, and the premedication for chemotherapy
  • Any concomitant drugs for use with the trial drugs according to the approved product information.
  • Known to trial drugs (cisplatin and docetaxel, durvalumab) or to any
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Durvalumab with 3 RT cohorts

    Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).

    Drug: Durvalumab · Radiation: Radiotherapy

Interventions

  • Immunotherapy

  • RadiationRadiotherapy

    Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS) at 12 months

    EFS is defined as time from registration to one of the following events, whichever occurs first: * Relapse or progression according to RECIST 1.1 criteria. * Second tumor * Death due to any cause Patients not experiencing an event will be censored at the date of last tumor assessment before starting a subsequent treatment, if any. As a sensitivity analysis, the primary endpoint will also be calculated according to the following definition of an event: * Progression during neoadjuvant treatment leading to inoperability * Recurrence of loco-regional disease after surgery * Appearance of metastases at any localization * Second tumor * Death due to any cause

    Time frame: at 12 months

Secondary outcomes

  1. Event-free survival (EFS)

    EFS is defined as time from registration to one of the following events, whichever occurs first: * Relapse or progression according to RECIST 1.1 criteria * Second tumor * Death due to any cause Patients not experiencing an event will be censored at the date of last tumor assessment before starting a subsequent treatment, if any. As a sensitivity analysis, the primary endpoint will also be calculated according to the following definition of an event: * Progression during neoadjuvant treatment leading to inoperability * Recurrence of loco-regional disease after surgery * Appearance of metastases at any localization * Second tumor * Death due to any cause

    Time frame: From the date of registration until the date of progressive disease, relapse, second tumor or death, whichever occurs first, assessed up to 20 years after registration

  2. Recurrence-free survival (RFS) after R0 resection

    RFS after R0 resection is defined as the time from surgery until one of the following events, whichever comes first: * Recurrence of loco-regional disease * Appearance of metastases at any localization * Death Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a subsequent treatment, if any. This endpoint will only be calculated for patients with R0 resection.

    Time frame: From the date of surgery until the date of recurrence of loco-regional disease, appearance of metastases, or death, whichever occurs first, assessed up to 20 years after registration

  3. Overall survival (OS)

    OS is defined as time from registration until death due to any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.

    Time frame: From the date of registration until the date of death from any cause, assessed up to 20 years after registration

  4. Objective response (OR) after neoadjuvant chemotherapy

    OR after neoadjuvant chemotherapy is defined as complete response (CR) or partial response (PR) at the first assessment after the end of neoadjuvant chemotherapy. Response will be evaluated according to RECIST 1.1 criteria. Patients without response assessment after the end of neoadjuvant chemotherapy and before the start of next trial treatment, if any, will be regarded as having a non-evaluable response (NE) and shall be considered as failures for this endpoint.

    Time frame: At the date of tumor assessment after neoadjuvant chemotherapy, estimated at approximately 9 weeks post-baseline

  5. OR after neoadjuvant immuno-radiotherapy

    OR after neoadjuvant immuno-radiotherapy is defined as complete response (CR) or partial response (PR) at the first assessment after the end of neoadjuvant immuno-radiotherapy. Response will be evaluated according to RECIST 1.1 criteria. Patients without response assessment after the end of neoadjuvant immuno-radiotherapy before the start of next trial treatment, if any, will be regarded as having a non-evaluable response (NE) and shall be considered as failures for this endpoint.

    Time frame: At the date of tumor assessment after neoadjuvant immune-radiotherapy, estimated at approximately 13 weeks post-baseline

  6. Pathological Complete Response (pCR)

    pCR is defined as complete tumor regression with no evidence of vital tumor cells in the sections of the primary lesion and mediastinal lymph nodes after surgery . Patients who were not resected will not be taken into consideration for this endpoint. Results from Central Pathology will be used.

    Time frame: At the date of tumor assessment after surgery, estimated at approximately 15 weeks post-baseline

  7. Local Major pathological response (MPR)

    Local Major pathologic response (MPR) is defined as the presence of 10% or less of vital tumor cells in the sections of the primary lesion - without taking into account the presence or extent/viability of tumor cells in the lymph nodes presenting. Patients who were not resected will not be taken into consideration for this endpoint. Results from Central Pathology will be used.

    Time frame: At the date of tumor assessment after surgery, estimated at approximately 15 weeks post-baseline

  8. Overall Major pathological response (oMPR)

    Overall Major pathologic response (oMPR) is defined as the presence of 10% or less of vital tumor cells in the sections of the primary lesion and/or mediastinal lymph nodes presenting focal microscopic disease after surgery Patients who were not resected will not be taken into consideration for this endpoint. Results from Central Pathology will be used.

    Time frame: At the date of tumor assessment after surgery, estimated at approximately 15 weeks post-baseline

  9. Nodal down-staging to < ypN2

    Nodal down-staging to \< ypN2 is defined as the case where after the surgery the remaining node status of the patients according to the TNM cancer staging system is less than N2 (N0/1). Patients who were not resected will not be taken into consideration for this endpoint.

    Time frame: At the date of tumor assessment after surgery, estimated at approximately 15 weeks post-baseline

  10. Complete resection

    Complete resection is defined as fulfillment of all the following criteria, according to: * free resection margins proved microscopically (R0 resection) * systematic nodal dissection or lobe-specific systematic nodal dissection * no extracapsular nodal extension of the tumor * the highest mediastinal node removed must be negative Patients who were not resected will not be taken into consideration for this endpoint.

    Time frame: At the date of tumor assessment after surgery, estimated at approximately 15 weeks post-baseline

07

Study locations

13 sites
08

References and documents

Publications

  • Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, Vrijmoet A, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. J Immunother Cancer. 2024 Sep 30;12(9):e009799. doi: 10.1136/jitc-2024-009799. PubMed 39349061 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 76 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 29, 2020
StartActual
Jul 15, 2020
Primary completionEst.
Dec 7, 2026was Jul 2026
CompletionEst.
Dec 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 16, 2026→Dec 7, 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jul 16, 2026→Dec 7, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04245514
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Jul 15, 2020
Primary completion
Dec 7, 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Sacha Rothschild, MD
study chair · Universitätsspital Basel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion